Forums
New posts
Search forums
What's new
New posts
New media
New media comments
Latest activity
Classifieds
Media
New media
New comments
Search media
Log in
Register
What's New?
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More Options
Advertise with us
Contact Us
Close Menu
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Forums
The Water Cooler
General Discussion
The natural china flu vaccine (getting it) might stop future colds
Search titles only
By:
Reply to Thread
This site may earn a commission from merchant affiliate links, including eBay, Amazon, and others.
Message
<blockquote data-quote="sherrick13" data-source="post: 3638264" data-attributes="member: 9406"><p>Having chinaflu natural immunity might help from getting some common colds in the future too.</p><p></p><p>You will NEVER hear about this from the US .gov.</p><p></p><p></p><p></p><p></p><p><a href="https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2" target="_blank">Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells: Cell Reports Medicine</a></p><p></p><p></p><p><em></em></p><p><em>COVID-19 infection results in increased levels of antibodies to two common human betacoronaviruses (HKU1 and OC43) and to SARS-CoV-1</em></p><p><em></em></p><p><em>We next examined if SARS-CoV-2 infection had any impact on the levels of antibodies to the other human coronaviruses. We measured IgG, IgA, and IgM antibody binding to the spike proteins of other known human coronaviruses in the COVID-19 patients (n = 222 for IgG and n = 190 for IgA and IgM) and compared these data to the 51 pre-pandemic healthy donor samples. In the COVID-19 patients, IgG and IgA antibodies to the alphacoronaviruses 229E and NL63 did not show any significant changes compared to the antibody levels in the pre-pandemic healthy controls (<a href="https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2#fig2" target="_blank">Figures 2</a>A, 2B, 2F, and 2G; <a href="https://www.cell.com/cms/10.1016/j.xcrm.2021.100354/attachment/864a588f-0cdb-4128-8a7a-1213e298b2e6/mmc1" target="_blank">Figures S1</a>C and S1D). In contrast, the IgG and IgA antibodies to betacoronaviruses HKU1 and OC43 were substantially elevated in COVID-19 patients relative to pre-pandemic controls (<a href="https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2#fig2" target="_blank">Figures 2</a>C, 2D, 2H, and 2I; <a href="https://www.cell.com/cms/10.1016/j.xcrm.2021.100354/attachment/864a588f-0cdb-4128-8a7a-1213e298b2e6/mmc1" target="_blank">Figures S1</a>C and S1D; p < 0.0001). After this boost, HKU1 and OC43 IgG antibody levels declined with estimated half-lives of 288 (95% CI [235, 372]) and 212 (95% CI [176, 268]) days, respectively (exponential decay model). IgM levels to common betacoronaviruses HKU1 and OC43 were low in both pre-pandemic controls and COVID-19 patients (<a href="https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2#fig2" target="_blank">Figures 2</a>M and 2N). While pre-existing exposure and antibodies against HKU1 and OC43 betacoronaviruses are common in adults, pre-existing SARS-CoV-1 exposure is rare and antibody levels to SARS-CoV-1 spike protein were very low (essentially negative) in the pre-pandemic healthy controls. However, SARS-CoV-1 spike-reactive antibodies increased significantly after SARS-CoV-2 infection. These increases were quite striking for IgG (p = 0.0038) and also IgA (p = 0.0084) and most likely represent cross-reactive antibodies directed to SARS-CoV-2 spike epitopes that are conserved between SARS-CoV-2 and SARS CoV-1</em></p><p><em></em></p><p><em>These newly induced cross-reactive IgG antibodies generated after COVID-19 infection declined with an estimated half-life of 215 days (95% CI [168, 298]) (exponential decay model) (<a href="https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2#fig2" target="_blank">Figure 2</a>). Taken together, these results show that people infected with SARS-CoV-2 may have also have some heightened immunity against the common human betacoronaviruses and more importantly against </em></p></blockquote><p></p>
[QUOTE="sherrick13, post: 3638264, member: 9406"] Having chinaflu natural immunity might help from getting some common colds in the future too. You will NEVER hear about this from the US .gov. [URL='https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2']Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells: Cell Reports Medicine[/URL] [I] COVID-19 infection results in increased levels of antibodies to two common human betacoronaviruses (HKU1 and OC43) and to SARS-CoV-1 We next examined if SARS-CoV-2 infection had any impact on the levels of antibodies to the other human coronaviruses. We measured IgG, IgA, and IgM antibody binding to the spike proteins of other known human coronaviruses in the COVID-19 patients (n = 222 for IgG and n = 190 for IgA and IgM) and compared these data to the 51 pre-pandemic healthy donor samples. In the COVID-19 patients, IgG and IgA antibodies to the alphacoronaviruses 229E and NL63 did not show any significant changes compared to the antibody levels in the pre-pandemic healthy controls ([URL='https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2#fig2']Figures 2[/URL]A, 2B, 2F, and 2G; [URL='https://www.cell.com/cms/10.1016/j.xcrm.2021.100354/attachment/864a588f-0cdb-4128-8a7a-1213e298b2e6/mmc1']Figures S1[/URL]C and S1D). In contrast, the IgG and IgA antibodies to betacoronaviruses HKU1 and OC43 were substantially elevated in COVID-19 patients relative to pre-pandemic controls ([URL='https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2#fig2']Figures 2[/URL]C, 2D, 2H, and 2I; [URL='https://www.cell.com/cms/10.1016/j.xcrm.2021.100354/attachment/864a588f-0cdb-4128-8a7a-1213e298b2e6/mmc1']Figures S1[/URL]C and S1D; p < 0.0001). After this boost, HKU1 and OC43 IgG antibody levels declined with estimated half-lives of 288 (95% CI [235, 372]) and 212 (95% CI [176, 268]) days, respectively (exponential decay model). IgM levels to common betacoronaviruses HKU1 and OC43 were low in both pre-pandemic controls and COVID-19 patients ([URL='https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2#fig2']Figures 2[/URL]M and 2N). While pre-existing exposure and antibodies against HKU1 and OC43 betacoronaviruses are common in adults, pre-existing SARS-CoV-1 exposure is rare and antibody levels to SARS-CoV-1 spike protein were very low (essentially negative) in the pre-pandemic healthy controls. However, SARS-CoV-1 spike-reactive antibodies increased significantly after SARS-CoV-2 infection. These increases were quite striking for IgG (p = 0.0038) and also IgA (p = 0.0084) and most likely represent cross-reactive antibodies directed to SARS-CoV-2 spike epitopes that are conserved between SARS-CoV-2 and SARS CoV-1 These newly induced cross-reactive IgG antibodies generated after COVID-19 infection declined with an estimated half-life of 215 days (95% CI [168, 298]) (exponential decay model) ([URL='https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2#fig2']Figure 2[/URL]). Taken together, these results show that people infected with SARS-CoV-2 may have also have some heightened immunity against the common human betacoronaviruses and more importantly against [/I] [/QUOTE]
Insert Quotes…
Verification
Post Reply
Forums
The Water Cooler
General Discussion
The natural china flu vaccine (getting it) might stop future colds
Search titles only
By:
Top
Bottom